ArticleFrontiers in immunology2025

Dual targeting of joint and lung disease: efficacy of tofacitinib plus iguratimod combination in progressive fibrosing rheumatoid arthritis-associated interstitial lung disease.

Yuan Zhu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.